SOLICITATION NOTICE
A -- Medications Development for Stimulant Dependence 3 (MDS 3)
- Notice Date
- 11/30/2007
- Notice Type
- Solicitation Notice
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6101 Executive Boulevard Room 260 - MSC 8402, Bethesda, MD, 20892, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- N01DA-8-8878
- Point of Contact
- Pedro Godinez, Contract Specialist, Phone 301.443.6677, Fax 301.443.7595, - Kenneth Goodling, Contracting Officer, Phone (301)443-6677, Fax (301)443-7595
- E-Mail Address
-
pg186o@nih.gov, kg25d@nih.gov
- Description
- The National Institute on Drug Abuse (NIDA) plans to solicit proposals from qualified investigational sites having the capability to conduct Phase I and/or Phase II and Phase III clinical trials of potential treatment medications, both investigational and marketed, for treatment of (1) stimulant abuse and dependence (i.e., cocaine, or methamphetamine), (2) codependence with alcohol and stimulants, (3) nicotine dependence and (4) marijuana abuse and dependence. Specifically, interested parties must be capable of conducting clinical trials to investigate the efficacy and safety of medications for the treatment of stimulant addiction, codependence with stimulants and alcohol, and nicotine under the current Food and Drug Administration regulations and ICH guidelines. NIDA will supply the study protocol and database management services. Those interested must be able to provide all other necessary services to conduct clinical trials.
- Record
- SN01461033-W 20071202/071201074131 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |